LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer.
Commun Biol
; 4(1): 1235, 2021 10 29.
Article
in En
| MEDLINE
| ID: mdl-34716410
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Leukemia Inhibitory Factor Receptor alpha Subunit
/
Histone Deacetylase Inhibitors
/
Triple Negative Breast Neoplasms
/
Antineoplastic Agents
Type of study:
Prognostic_studies
Limits:
Animals
Language:
En
Journal:
Commun Biol
Year:
2021
Type:
Article
Affiliation country:
United States